REVELATION BIOSCIENCES

Company snapshot

We are a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for REVELATION BIOSCIENCES. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for REVELATION BIOSCIENCES.

1. Jun 5, 2026 Clinical update

   Intravenous Gemini — Phase 2

2. Jul 29, 2025 Patent grant

   Purification of clinoptilolite

3. Apr 18, 2023 Patent grant

   Purification of clinoptilolite

View all clinical trial activity →

• What is REVELATION BIOSCIENCES?

  Revelation Biosciences is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker REVB. Primary therapeutic focus areas include Renal Insufficiency, Chronic. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 2 patent record(s) to thi

• Is REVELATION BIOSCIENCES publicly traded?

  Yes. REVELATION BIOSCIENCES is listed with ticker REVB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does REVELATION BIOSCIENCES develop or market?

  We link 1 drug profile(s) where REVELATION BIOSCIENCES is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/revelation-biosciences-inc#company-drugs.

• What are the latest developments for REVELATION BIOSCIENCES?

  In the last 12 months our linked public records show 1 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does REVELATION BIOSCIENCES focus on?

  REVELATION BIOSCIENCES focuses on Renal Insufficiency, Chronic based on our analysis of their pipeline programs and drug development activities.